The Effectiveness and Safety of Landiolol Hydrochloride, an Ultra-Short-Acting β(1)-Blocker, in Postoperative Patients with Supraventricular Tachyarrhythmias: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Samankaltaisia teoksia

• Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β(1)-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients
  Tekijä: Taenaka, Nobuyuki, et al.
  Julkaistu: (2013)
• Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis
  Tekijä: Okajima, Masaki, et al.
  Julkaistu: (2015)
• Efficacy of Intravenous Administration of Landiolol in Patients With Acute Heart Failure and Supraventricular Tachyarrhythmia
  Tekijä: Kiuchi, Shunsuke, et al.
  Julkaistu: (2017)
• Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction
  Tekijä: Wada, Yuko, et al.
  Julkaistu: (2016)
• A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease
  Tekijä: Jinzaki, Masahiro, et al.
  Julkaistu: (2013)